TLDR: Qanatpharma, Zuse Institute Berlin, Enamine, and Proteros biostructures have announced a collaborative research program aimed at accelerating the discovery of novel therapeutics. This international effort will utilize generative AI-powered drug discovery to develop a first-in-class therapy to prevent delayed cerebral ischemia (DCI), a life-threatening complication in patients suffering from subarachnoid hemorrhage (SAH). The initiative addresses a critical unmet medical need in stroke recovery.
STANS, Switzerland, TORONTO, Canada, MUNICH, Germany, BERLIN, Germany, and KYIV, Ukraine – July 9, 2025 – A significant international collaboration has been launched today, bringing together Qanatpharma (QP), Zuse Institute Berlin (ZIB), Enamine, and Proteros biostructures. The joint research program is set to revolutionize drug discovery by harnessing advanced generative AI technologies to develop novel treatments for a severe complication of brain hemorrhage.
The primary objective of this collaboration is to accelerate the discovery of therapeutics specifically targeting cerebral perfusion deficits associated with subarachnoid hemorrhage (SAH). SAH is a severe form of stroke resulting from bleeding into the space surrounding the brain. A major and often devastating complication for SAH survivors is delayed cerebral ischemia (DCI), a condition characterized by reduced cerebral perfusion that significantly contributes to long-term neurological damage, disability, and even death. Current treatment options, such as the calcium channel blocker Nimodipine, have proven largely ineffective in addressing the underlying molecular mechanisms of DCI, highlighting a critical unmet medical need.
Qanatpharma initiated this groundbreaking program by identifying a crucial protein target involved in regulating cerebrovascular resistance within the brain, a mechanism known to be compromised in SAH patients. The collaborative effort will then leverage the distinct expertise of each partner across the drug discovery and development pipeline.
Zuse Institute Berlin (ZIB) will lead the early stages of the program, focusing on generative molecular design and docking studies, utilizing its proprietary algorithms to create innovative molecular structures. Following this, Enamine, recognized as the world’s largest supplier of make-on-demand small molecules, will undertake the REAL®-directed compound synthesis, bringing the designed molecules to fruition. Finally, Proteros biostructures will play a pivotal role in the validation of hit compounds, employing their sophisticated structure-based drug discovery platform to confirm the efficacy and potential of the newly synthesized molecules.
Also Read:
- Chugai, a Roche Subsidiary, Forges Landmark $1 Billion+ AI Partnership with Gero to Combat Aging Diseases
- Insilico Medicine to Unveil Summer 2025 Advancements in Pharma.ai for AI-Driven Medical Research
This pioneering program is expected to set a new precedent for the application of generative AI technologies in accelerating early-stage drug discovery, particularly within the complex field of cerebrovascular conditions. The alliance represents a concerted effort to deliver a first-in-class therapy that could significantly improve outcomes for patients suffering from subarachnoid hemorrhage by preventing delayed cerebral ischemia.
